US 2026/0284082 A1Published application

Targeting the panx1-p2y2r-trpv4 pathway to treat lung ischemia-reperfusion injury

OwnerSwapnil Sonkusare, Victor Laubach +1inventors

InventorsSwapnil Sonkusare, Victor Laubach, Huy Ta

Life of this patent

Estimating the term…

Abstract

Provided herein are methods for treating lung ischemia-reperfusion injury (IRI) by targeting the purinergic P2Y2 receptor (P2Y2R) and other members of the Panx1-P2Y2R-TRPV4 signaling pathway.

Claims20

Dependent claims

A method for treating lung ischemia-reperfusion injury (IRI) in a subject in need thereof, the method comprising administering to the subject a P2Y2 receptor (P2Y2R) inhibitor.

Dependencies are inferred from the claim text.

Facts

Application: 19/474,695Filed 12 Apr 2024
Priority: 14 Apr 2023
Published: 24 Sep 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/585
Containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin: containing lactone rings, e.g. oxandrolone, bufalin
A61P 9/10
Drugs for disorders of the cardiovascular system: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary…
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/407
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with other…

Family

Application63/496,215Us provisional application · filed 14 Apr 2023
US 2026/0284082 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results